dalteparin has been researched along with Dyspareunia in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Dyspareunia: Recurrent genital pain occurring during, before, or after SEXUAL INTERCOURSE in either the male or the female.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farajun, Y | 1 |
| Zarfati, D | 1 |
| Abramov, L | 1 |
| Livoff, A | 1 |
| Bornstein, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia[NCT00874484] | Phase 2 | 40 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Dyspareunia
| Article | Year |
|---|---|
Enoxaparin treatment for vulvodynia: a randomized controlled trial.
Topics: Adolescent; Adult; Biopsy; Double-Blind Method; Drug Administration Schedule; Dyspareunia; Enoxapari | 2012 |